IRVINE, CA--(Marketwire - April 27, 2010) - The addition of Ray Dawkins, MD, to Paragon Biomedical's professional staff bolsters the company's expertise in ways that will help biopharmaceutical and medical device companies conserve closely-managed resources, according to Mark Harvill, President and Chief Operating Officer of the global clinical research organization (CRO).
Harvill said Dawkins' broad experience, which includes medical and scientific leadership roles at biopharmaceutical companies and CROs, provides the balanced perspective critical to success in today's clinical research environment.
Dawkins joined Paragon on April 19 as Executive Medical Director. He will lead the company's global Medical Affairs team for continued growth across the full-service CRO's Phase I-IV clinical research services.
"We're really excited about having Ray join our team," said Harvill. "He's seen clinical research from all vantage points; as a sponsor and within CROs, and has extensive experience outside the US. He understands resource management. He knows how to navigate the regulatory environment. And, just as important, he is completely attuned to the relationship dynamics among sponsor organizations, CROs, and vendors."
Paragon is "the perfect fit" for meeting the needs of large segments of the biopharmaceutical market, Dawkins said.
"Exciting work is taking place at small and mid-sized companies right now," he said. "Unfortunately, those companies often don't get the attention they need from the really large CROs. It is clear that Paragon has not lost touch with the needs of biopharmaceutical companies. They know how to put together customized solutions regardless of the sponsor's size or global reach."
Dawkins has nearly 30 years of experience in healthcare and clinical research. Before joining Paragon, he was Senior Medical Director at a global biotherapeutic and biotechnology company. He has strong experience in several therapeutic areas, including cardiovascular, infectious disease, endocrinology, gastroenterology, and recent work in plasma-derived proteins and products.
Since 2005, Dawkins has conducted medical device research and development for delivery systems and the design of new intravascular catheters for cardiovascular indications (peripheral arterial disease and stroke).
With offices in the United States, United Kingdom, and India, Paragon Biomedical is a global, full-service CRO providing Phase I through IV clinical research services and clinical trial support to the world's pharmaceutical, biotechnology, and medical device companies.
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati:
